$PTCT: PTC Therapeutics Reports Q3 Revenue of $358M, Raises FY26 Revenue Guid

$PTCT

$PTCT – PTC Therapeutics Reports Q3 Revenue of $358M, Raises FY26 Revenue Guidance to Up to $1.32B

PTC THERAPEUTICS, INC.

2026-10-29 00:00:00 UTC · SEC_8K · All $PTCT

?? Positive AI Sentiment (+4.5 / 10)

Total Q3 revenue reached $358M, driven by $276M in product revenue including $182M from Sephience.
FY2026 total revenue guidance raised to $1.29B–$1.32B (product revenue raised to $960M–$990M).
Q3 GAAP net loss was $51.7M (EPS -$0.62) while cash and equivalents closed at $2.13B.